<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="pmc-domain-id">2786</journal-id><journal-id journal-id-type="pmc-domain">medicine</journal-id><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12431723</article-id><article-id pub-id-type="pmcid-ver">PMC12431723.1</article-id><article-id pub-id-type="pmcaid">12431723</article-id><article-id pub-id-type="pmcaiid">12431723</article-id><article-id pub-id-type="pmid">39252316</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000039308</article-id><article-id pub-id-type="publisher-id">MD-D-24-03618</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>4800</subject></subj-group><subj-group><subject>Research Article</subject><subject>Narrative Review</subject></subj-group></article-categories><title-group><article-title>Use and effectiveness of PCSK-9 inhibitors in heart diseases: A review</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0636-7685</contrib-id><name name-style="western"><surname>Alorfi</surname><given-names initials="NM">Nasser M.</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="c1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Harbi</surname><given-names initials="MH">Maan H.</given-names></name><degrees>PhD</degrees><email>mhiharbi@uqu.edu.sa</email><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>El Hajj</surname><given-names initials="MS">Maguy Saffouh</given-names></name><degrees>PharmD, BCPS</degrees><email>maguyh@qu.edu.qa</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alayoubi</surname><given-names initials="S">Samha</given-names></name><degrees>PhD</degrees><email>f_al_ayoubi@yahoo.com</email><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names initials="NA">Nihal Abdalla</given-names></name><degrees>PhD</degrees><email>n.ibrahim@ajman.ac.ae</email><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alayoubi</surname><given-names initials="FZ">Fakhr Z.</given-names></name><degrees>ASCP</degrees><email>f_al_ayoubi@yahoo.com</email><xref rid="aff6" ref-type="aff">f</xref></contrib><aff id="aff1"><label>a</label> Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia</aff><aff id="aff2"><label>b</label> College of Pharmacy, QU Health, Qatar University, Doha, Qatar</aff><aff id="aff3"><label>c</label> Department of Mathematics and Sciences, College of Humanities and Sciences, Prince Sultan University, Riyadh, Saudi Arabia</aff><aff id="aff4"><label>d</label> College of Pharmacy, Ajman University, Ajman, United Arab Emirates</aff><aff id="aff5"><label>e</label> Center of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates</aff><aff id="aff6"><label>f</label> Department of Cardiac Sciences KFCC, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.</aff></contrib-group><author-notes><corresp id="c1"><label>*</label>Correspondence: Nasser M. Alorfi, Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia (e-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nmorfi@uqu.edu.sa">nmorfi@uqu.edu.sa</email>).</corresp></author-notes><pub-date pub-type="collection"><day>06</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>06</day><month>9</month><year>2024</year></pub-date><volume>103</volume><issue>36</issue><issue-id pub-id-type="pmc-issue-id">470382</issue-id><elocation-id>e39308</elocation-id><history><date date-type="received"><day>04</day><month>4</month><year>2024</year></date><date date-type="received"><day>20</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>25</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>09</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CCBY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="medi-103-e39308.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="medi-103-e39308.pdf"/><abstract><p>Proprotein Convertase Subtilisin/Kexin type-9 (PCSK-9) inhibitors have recently used in the management of different cardiac complications. Several clinical trials demonstrated their effectiveness in patients with hypercholesterolemia. However, the effectiveness of these medications in patients with heart diseases is still controversial. To review and summarize the clinical trials pertaining to the use and effectiveness of PCSK-9 inhibitors in heart diseases and to discuss the pharmacotherapy of these agents. A review was conducted of all clinical trials with PCSK-9 inhibitors for heart diseases registered at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> since inception up to and including January 19th, 2024. These trials were retrieved. Data from these trials were extracted manually, categorized and analyzed. The number of identified clinical trials was 25,371. After screening and excluding irrelevant studies, 12 studies met the search criteria. The majority of these studies were conducted in the US. The total number of patients in these studies was 27,700. Alirocumab and Evolocumab were the most frequently used PCSK-9 inhibitors. This review identified only a few clinical trials on PCSK-9 inhibitors in heart disease patients. Therefore, it is recommended to conduct more randomized controlled clinical trials on PCSK-9 inhibitors in this patient population.</p></abstract><kwd-group><kwd>Alirocumab</kwd><kwd>Clinical trials</kwd><kwd>Evolocumab</kwd><kwd>Heart diseases</kwd><kwd>PCSK-9 inhibitors</kwd></kwd-group><funding-group><award-group id="ID0EU4AE125450"><funding-source>none</funding-source><award-id>none</award-id><principal-award-recipient>Not Applicable</principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>1. Introduction</title><p>Heart disease is a major global health issue and a leading cause of death in numerous countries, including the Middle East.<sup>[<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>]</sup> Approximately 17.9 million people worldwide die from cardiovascular diseases (CVDs) each year.<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> Heart attacks and stroke account for more than 4 out of 5 CVD deaths, and approximately 30% of these deaths occur prematurely in individuals under 70 years old.<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup></p><p>Several crucial behavioral risk factors significantly contribute to the development of heart diseases. Poor dietary choices, for example an excessive consumption of saturated and trans saturated fats and high intake of salt, and sugar, can cause obesity, hypertension, and dyslipidemia, all of which are key drivers of cardiovascular issues.<sup>[<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref>]</sup> Sedentary lifestyles, characterized by limited physical activity and prolonged periods of sitting, can also weaken the heart and the circulatory system over time.<sup>[<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>]</sup> Furthermore, smoking is another major behavioral risk factor, as it damages blood vessels, reduces oxygen supply, and increases the likelihood of blood clots.<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>]</sup> Additionally, chronic stress and inadequate stress management can trigger inflammation, raise blood pressure, and strain the heart.<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup> Addressing these risk factors through behavioral interventions such as healthy eating habits, regular exercise, smoking cessation, and stress reduction techniques are crucial in preventing and managing heart diseases.</p><p>Proprotein Convertase Subtilisin/Kexin type-9 (PCSK-9) has arisen as a crucial player in the realm of CVDs. PCSK-9 functions by regulating cholesterol levels within the body.<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup> PCSK-9 is an enzyme produced primarily in the liver<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup> and attaches to the low-density lipoprotein (LDL) receptors on the outer part of liver cells.<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup> These receptors play a vital role in removing LDL cholesterol, also known as &#8220;bad cholesterol,&#8221; from the bloodstream. However, when PCSK-9 binds to these receptors, it triggers a process that leads to their degradation and reduces their ability to clear LDL cholesterol from the blood.<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup> This leads to increased levels of LDL cholesterol in the bloodstream, significantly raising the risk of CVDs.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> Inhibiting PCSK-9&#8217;s activity has become a therapeutic strategy to lower LDL cholesterol levels.<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> Monoclonal antibodies targeting PCSK-9, when introduced into the body, can neutralize its function, allowing LDL receptors to remain active and effectively clear LDL cholesterol from the bloodstream. This approach has shown promise in managing elevated cholesterol levels and reducing the risk of heart diseases.<sup>[<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref>]</sup></p><sec><title>Aim:</title><p>To review and summarize the clinical trials pertaining to the use and effectiveness of PCSK-9 inhibitors in heart diseases and to discuss the pharmacotherapy of these agents.</p></sec></sec><sec sec-type="methods"><title>2. Methods</title><sec><title>Data sources and search strategy:</title><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> database was searched for clinical trials on the use of PCSK-9 inhibitors in heart diseases since inception up to and including January 19th, 2024. The search was conducted using &#8220;heart diseases&#8221; as the main keyword for conditions or diseases, with &#8220;PCSK-9&#8221; entered under the &#8220;other terms&#8221; section. A summary of the characteristics of the trials is obtained from the database, including the study title, conditions, interventions, phase, and number of patients enrolled.</p></sec><sec><title>Data extraction:</title><p>From the results reported in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> registry, data were manually retrieved, and analyzed, according to the following elements:</p><list list-type="bullet"><list-item><p>Interventions: Details of interventional (clinical trial), observational, and expanded access.</p></list-item><list-item><p>Conditions: The keyword of condition/disease for searching was &#8220;heart diseases,&#8221; and PCSK-9.</p></list-item><list-item><p>Trial design: All phases.</p></list-item><list-item><p>Location: Open to any location.</p></list-item><list-item><p>Study status: Completed and no longer looking for participants.</p></list-item></list></sec><sec><title>Terms and synonyms searched:</title><p>The keywords or search terms used to find relevant clinical trials within the database were tabulated in Table <xref rid="T1" ref-type="table">1</xref>.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Terms and synonyms used in the search.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Terms</th><th align="center" rowspan="1" colspan="1">Search results</th><th align="center" rowspan="1" colspan="1">Entire database</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">Synonyms</td></tr><tr><td align="left" rowspan="1" colspan="1">PCSK-9</td><td align="center" rowspan="1" colspan="1">67 studies</td><td align="center" rowspan="1" colspan="1">395 studies</td></tr><tr><td align="left" rowspan="1" colspan="1">PC9</td><td align="center" rowspan="1" colspan="1">&#8211;</td><td align="center" rowspan="1" colspan="1">3 studies</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart diseases</td><td align="center" rowspan="1" colspan="1">67 studies</td><td align="center" rowspan="1" colspan="1">25,201 studies</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiac disease</td><td align="center" rowspan="1" colspan="1">&#8211;</td><td align="center" rowspan="1" colspan="1">328 studies</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiac disorder</td><td align="center" rowspan="1" colspan="1">&#8211;</td><td align="center" rowspan="1" colspan="1">18 studies</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiopathies</td><td align="center" rowspan="1" colspan="1">&#8211;</td><td align="center" rowspan="1" colspan="1">28 studies</td></tr><tr><td align="left" rowspan="1" colspan="1">Disease hearts</td><td align="center" rowspan="1" colspan="1">&#8211;</td><td align="center" rowspan="1" colspan="1">1 study</td></tr><tr><td align="left" rowspan="1" colspan="1">Diseases of the heart</td><td align="center" rowspan="1" colspan="1">&#8211;</td><td align="center" rowspan="1" colspan="1">3 studies</td></tr><tr><td align="left" rowspan="1" colspan="1">Disorder heart</td><td align="center" rowspan="1" colspan="1">&#8211;</td><td align="center" rowspan="1" colspan="1">1 study</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart disorder</td><td align="center" rowspan="1" colspan="1">&#8211;</td><td align="center" rowspan="1" colspan="1">3 studies</td></tr></tbody></table></table-wrap></sec></sec><sec><title>3. Inclusion criteria</title><p>Completed and any phase clinical trials that were registered in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">Clinicaltrials.gov</ext-link> database using PCSK-9 inhibitors as major intervention and related to heart diseases until January 19th, 2024 were included in this review. Age and sex/gender were not considered for excluding any clinical trial. Clinical trials that did not involve PCSK-9 inhibitors as a major intervention were excluded along with trials that did not have results.</p></sec><sec sec-type="results"><title>4. Results</title><sec><title>Analysis of the number of research registrations:</title><p>A total of 25,371 registrations of clinical trials related to heart diseases were found in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> database. Records that were screened and studies that were completed were included. (n&#8197;=&#8197;12,791). Of them, only 12 used PCSK-9 drugs met the inclusion criteria.</p></sec><sec><title>Clinical trials characteristics:</title><p>Clinical trials characteristics including study title, conditions, interventions, phase, and number of enrolled patients are summarized in Table <xref rid="T2" ref-type="table">2</xref>.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Study title, conditions, interventions, phase and number enrolled (updated form <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> on October 19, 2024).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Study title</th><th align="center" rowspan="1" colspan="1">Conditions</th><th align="center" rowspan="1" colspan="1">Interventions</th><th align="center" rowspan="1" colspan="1">Phase</th><th align="center" rowspan="1" colspan="1">Number of patients/participants enrolled</th><th align="center" rowspan="1" colspan="1">Location</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Evolocumab in stable heart failure with reduced ejection fraction of ischemic etiology</td><td align="center" rowspan="1" colspan="1">Heart failure with reduced ejection fraction</td><td align="center" rowspan="1" colspan="1">Evolocumab</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">Spain</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">In-hospital initiation of PCSK-9 inhibitor in patients with acute myocardial infarction</td><td align="center" rowspan="1" colspan="1">Coronary disease</td><td align="center" rowspan="1" colspan="1">Evolocumab 140&#8201;mg/mL</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">7556</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Effect of evolocumab on coronary endothelial function</td><td align="center" rowspan="1" colspan="1">HIV<break/>CAD</td><td align="center" rowspan="1" colspan="1">Evolocumab</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">United States</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS)</td><td align="center" rowspan="1" colspan="1">Acute coronary syndrome</td><td align="center" rowspan="1" colspan="1">Evolocumab 140&#8201;mg/mL</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">308</td><td align="center" rowspan="1" colspan="1">Switzerland</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Alirocumab and reverse cholesterol transport</td><td align="center" rowspan="1" colspan="1">Atherosclerosis<break/>CAD</td><td align="center" rowspan="1" colspan="1">Alirocumab</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">United States</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">Effects of acute, rapid lowering of LDL cholesterol with Alirocumab in patients With STEMI undergoing primary PCI</td><td align="center" rowspan="1" colspan="1">Acute coronary syndrome<break/>Hypercholesterolemia</td><td align="center" rowspan="1" colspan="1">Alirocumab</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">Canada</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Alirocumab in patients with acute myocardial infarction</td><td align="center" rowspan="1" colspan="1">Myocardial infarction<break/>Hypercholesterolemia</td><td align="center" rowspan="1" colspan="1">Alirocumab</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">United States</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">Rosuvastatin and evolocumab for CAD</td><td align="center" rowspan="1" colspan="1">CAD</td><td align="center" rowspan="1" colspan="1">Statin<break/>Evolocumab</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">195</td><td align="center" rowspan="1" colspan="1">United States</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">Effect of evolocumab on coronary plaque characteristic</td><td align="center" rowspan="1" colspan="1">CAD</td><td align="center" rowspan="1" colspan="1">Evolocumab Injections</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">137</td><td align="center" rowspan="1" colspan="1">United States</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">Imaging of coronary plaques in participants treated With evolocumab</td><td align="center" rowspan="1" colspan="1">CAD</td><td align="center" rowspan="1" colspan="1">Evolocumab<break/>Statin therapy</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">164</td><td align="center" rowspan="1" colspan="1">United States</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab</td><td align="center" rowspan="1" colspan="1">Atherosclerotic cardiovascular disease</td><td align="center" rowspan="1" colspan="1">Alirocumab<break/>LMT</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">18924</td><td align="center" rowspan="1" colspan="1">United States</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">Evaluation of effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia</td><td align="center" rowspan="1" colspan="1">Hypercholesterolemia<break/>Acute coronary syndrome</td><td align="center" rowspan="1" colspan="1">Alirocumab<break/>Atorvastatin<break/>Rosuvastatin</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">206</td><td align="center" rowspan="1" colspan="1">Japan</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>HIV = human immunodeficiency virus; LMT = lipid modifying therapy; CAD = coronary artery diseases; NA = not applicable.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>PCSK-9 drugs usage:</title><p>Two drugs have been used, Alirocumab and Evolocumab, as shown in Table <xref rid="T2" ref-type="table">2</xref>.</p></sec><sec><title>Prisma chart:</title><p>Figure <xref rid="F1" ref-type="fig">1</xref> displays the identification of studies using the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">Clinicaltrials.gov</ext-link> database, updated on January 19, 2024.</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>PRISMA flow diagram of the search identified from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> database.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-103-e39308-g001.jpg"/></fig></sec></sec><sec sec-type="discussion"><title>5. Discussion</title><p>PCSK-9 inhibitors represent a promising class of lipid-lowering medications that have demonstrated a significant reduction in LDL-C levels and a decreased risk of major cardiovascular events in patients with heart disease. Utilization of PCSK-9 inhibitors in clinical practice is currently limited by their high cost and the lack of long-term safety data. It has been shown that Alirocumab is more effective than Evolocumab in high CV-risk patients whose LDL-C target goals were not met, while Evolocumab has stronger evidence in patients with heterogeneous familial hypercholesterolemia and patients with varied CV risks whose LDL-C target goals were not achieved.<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup></p><p>A monoclonal antibody, Alirocumab, binds to PCSK-9, preventing it from binding to LDL receptors on the surface of liver cells. This rises the number of LDL receptors on the surface of the liver cells, allowing more LDL cholesterol to be removed from the blood, thus lowering LDL cholesterol levels.<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup> A systematic review and meta-analysis of randomized clinical trials has demonstrated that Alirocumab significantly lowers LDL cholesterol levels by 45% to 62% compared to placebo, establishing it as an effective treatment for hypercholesterolemia.<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> The Food and Drug Administration has approved Alirocumab for adults who have established cardiovascular disease, are at high risk for cardiovascular disease, or have familial hypercholesterolemia. Alirocumab has been proven to decrease the risk of major cardiovascular events such as heart attacks and strokes in patients with existing cardiovascular disease, hence its labeled indication of secondary prevention of cardiovascular events.<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup></p><p>Among the medications that have been developed, Evolocumab is a human monoclonal immunoglobulin G2 that binds specifically to human PCSK-9.<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup> It is used to lower cholesterol levels in patients with CVDs such as coronary artery disease, stroke, and peripheral artery disease.<sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup> A systematic review and meta-analysis of randomized clinical trials has demonstrated that Evolocumab significantly decreases LDL cholesterol levels by 55% to 66% as compared to placebo, making it an effective treatment for hypercholesterolemia.<sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup> Evolocumab received the Food and Drug Administration approval for its use in adults with established or at high risk of CVDs as well as in adult and pediatric patients older than 10 years of age with familial hypercholesterolemia. This is due to clinical evidence showing that Evolocumab effectively lowers LDL cholesterol, which is a key risk factor for CVDs.<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup></p></sec><sec><title>6. Long-term effects of using PCSK-9 inhibitors</title><p>PCSK-9 inhibitors are a relatively new class of drugs, and their long-term effects are not yet fully known. Yet, the existing evidence indicated that they are generally safe and well-tolerated in the short to medium-term.<sup>[<xref rid="R26" ref-type="bibr">26</xref>]</sup></p><p>In clinical trials, PCSK-9 inhibitors have been shown to significantly reduce LDL cholesterol levels and to decrease the risk of cardiovascular events, such as heart attacks and strokes.<sup>[<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref>]</sup> However, the long-term effects on cardiovascular outcomes and mortality rates are still being studied. One concern with the long-term use of PCSK-9 inhibitors is the potential for adverse effects on the liver and kidneys. Some studies have suggested that these drugs may increase liver enzymes, which could indicate liver damage. However, the clinical importance of this result has not yet been established.<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup> Another potential concern is the development of anti-drug antibodies, which could diminish the effectiveness of these drugs over time. Nevertheless, this appears to be a relatively rare occurrence with PCSK-9 inhibitors.<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup> As with all medications, patients receiving PCSK-9 inhibitors should be monitored for potential side effects, and a careful evaluation of the benefits versus risks of the treatment should be conducted.</p></sec><sec><title>7. Conclusion</title><p>In conclusion, PCSK-9 inhibitors present a promising therapeutic avenue for heart patients, particularly those with elevated cholesterol levels and heightened cardiovascular risk. These inhibitors demonstrate notable effectiveness in significantly reducing LDL cholesterol levels, addressing a crucial risk factor for CVDs. By offering a potent adjunct to standard therapies, such as lifestyle modifications and statins, PCSK-9 inhibitors have demonstrated a potential in lowering the occurrence of major adverse cardiovascular events. However, personalized evaluation of patient profiles, considerations of cost and accessibility, and collaboration with healthcare providers remain essential in optimizing the use of these medications to enhance heart health outcomes.</p></sec><sec><title>Acknowledgments</title><p>The author (SA) would like to thank Prince Sultan University, Riyadh for their support. The author (FA) would like to thank Saudi cardio clinical pharmacy group at Saudi Heart Association for their valuable support at this work.</p></sec><sec><title>Author contributions</title><p><bold>Project administration:</bold> Fakhr Z. Alayoubi.</p><p><bold>Resources:</bold> Nasser M. Alorfi, Samha Alayoubi.</p><p><bold>Supervision:</bold> Nasser M. Alorfi.</p><p><bold>Validation:</bold> Nasser M. Alorfi, Maguy Saffouh El Hajj, Nihal Abdalla Ibrahim.</p><p><bold>Visualization:</bold> Nasser M. Alorfi.</p><p><bold>Writing &#8211; original draft:</bold> Nasser M. Alorfi, Fakhr Z. Alayoubi.</p><p><bold>Writing &#8211; review &amp; editing:</bold> Nasser M. Alorfi, Fakhr Z. Alayoubi, Maan H. Harbi, Maguy Saffouh El Hajj.</p></sec></body><back><fn-group><fn fn-type="abbr"><p>
<def-list><title>Abbreviations:</title><def-item><term>CVDs</term><def><p>cardiovascular diseases</p></def></def-item><def-item><term>LDL</term><def><p>low-density lipoprotein</p></def></def-item><def-item><term>PCSK-9</term><def><p>Proprotein Convertase Subtilisin/Kexin type-9</p></def></def-item></def-list>
</p></fn></fn-group><fn-group><fn fn-type="COI-statement"><p>The authors have no funding and conflicts of interest to disclose.</p></fn><fn fn-type="other"><p>The datasets generated during and/or analyzed during the current study are publicly available.</p></fn><fn fn-type="other"><p>How to cite this article: Alorfi NM, Harbi MH, El Hajj MS, Alayoubi S, Ibrahim NA, Alayoubi FZ. Use and effectiveness of PCSK-9 inhibitors in heart diseases: A review. Medicine 2024;103:36(e39308).</p></fn></fn-group><ref-list id="r2"><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#237;ez</surname><given-names>J</given-names></name><name name-style="western"><surname>Butler</surname><given-names>J</given-names></name></person-group>. <article-title>Growing heart failure burden of hypertensive heart disease: a call to action.</article-title><source>Hypertension</source>. <year>2023</year>;<volume>80</volume>:<fpage>13</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">36082670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/HYPERTENSIONAHA.122.19373</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lippi</surname><given-names>G</given-names></name><name name-style="western"><surname>Sanchis-Gomar</surname><given-names>F</given-names></name></person-group>. <article-title>Global epidemiology and future trends of heart failure.</article-title><source>AME Med J</source>. <year>2020</year>;<volume>5</volume>:<fpage>15</fpage>&#8211;<lpage>15</lpage>.</mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="webpage"><collab>World Health Orgnization</collab>. <article-title>Cardiovascular diseases 2023.</article-title><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1" ext-link-type="uri">https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1</ext-link>. Accessed August 23, 2023</comment>.</mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kundu</surname><given-names>J</given-names></name><name name-style="western"><surname>Kundu</surname><given-names>S</given-names></name></person-group>. <article-title>Cardiovascular disease (CVD) and its associated risk factors among older adults in India: evidence from LASI wave 1.</article-title><source>Clin Epidemiol Glob Health</source>. <year>2022</year>;<volume>13</volume>:<fpage>100937</fpage>.</mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kazemi</surname><given-names>A</given-names></name><name name-style="western"><surname>Sasani</surname><given-names>N</given-names></name><name name-style="western"><surname>Mokhtari</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Comparing the risk of cardiovascular diseases and all-cause mortality in four lifestyles with a combination of high/low physical activity and healthy/unhealthy diet: a prospective cohort study.</article-title><source>Int J Behav Nutr Phys Act</source>. <year>2022</year>;<volume>19</volume>:<fpage>1</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">36384713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12966-022-01374-1</pub-id><pub-id pub-id-type="pmcid">PMC9670610</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anand</surname><given-names>SS</given-names></name><name name-style="western"><surname>Hawkes</surname><given-names>C</given-names></name><name name-style="western"><surname>De Souza</surname><given-names>RJ</given-names></name><etal/></person-group>. <article-title>Food consumption and its impact on cardiovascular disease: importance of solutions focused on the globalized food system: a report from the workshop convened by the World Heart Federation.</article-title><source>J Am Coll Cardiol</source>. <year>2015</year>;<volume>66</volume>:<fpage>1590</fpage>&#8211;<lpage>614</lpage>.<pub-id pub-id-type="pmid">26429085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2015.07.050</pub-id><pub-id pub-id-type="pmcid">PMC4597475</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Same</surname><given-names>RV</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>DI</given-names></name><name name-style="western"><surname>Shah</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Relationship between sedentary behavior and cardiovascular risk.</article-title><source>Curr Cardiol Rep</source>. <year>2016</year>;<volume>18</volume>:<fpage>1</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">26699633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11886-015-0678-5</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le&#243;n-Latre</surname><given-names>M</given-names></name><name name-style="western"><surname>Moreno-Franco</surname><given-names>B</given-names></name><name name-style="western"><surname>Andr&#233;s-Esteban</surname><given-names>EM</given-names></name><etal/></person-group>. <article-title>Sedentary lifestyle and its relation to cardiovascular risk factors, insulin resistance and inflammatory profile.</article-title><source>Rev Esp Cardiol (Engl Ed)</source>. <year>2014</year>;<volume>67</volume>:<fpage>449</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">24863593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.rec.2013.10.015</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ambrose</surname><given-names>JA</given-names></name><name name-style="western"><surname>Barua</surname><given-names>RS</given-names></name></person-group>. <article-title>The pathophysiology of cigarette smoking and cardiovascular disease: an update.</article-title><source>J Am Coll Cardiol</source>. <year>2004</year>;<volume>43</volume>:<fpage>1731</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15145091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2003.12.047</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duncan</surname><given-names>MS</given-names></name><name name-style="western"><surname>Freiberg</surname><given-names>MS</given-names></name><name name-style="western"><surname>Greevy</surname><given-names>RA</given-names></name><name name-style="western"><surname>Kundu</surname><given-names>S</given-names></name><name name-style="western"><surname>Vasan</surname><given-names>RS</given-names></name><name name-style="western"><surname>Tindle</surname><given-names>HA</given-names></name></person-group>. <article-title>Association of smoking cessation with subsequent risk of cardiovascular disease.</article-title><source>JAMA</source>. <year>2019</year>;<volume>322</volume>:<fpage>642</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">31429895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.10298</pub-id><pub-id pub-id-type="pmcid">PMC6704757</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franklin</surname><given-names>BA</given-names></name><name name-style="western"><surname>Rusia</surname><given-names>A</given-names></name><name name-style="western"><surname>Haskin-Popp</surname><given-names>C</given-names></name><name name-style="western"><surname>Tawney</surname><given-names>A</given-names></name></person-group>. <article-title>Chronic stress, exercise and cardiovascular disease: placing the benefits and risks of physical activity into perspective.</article-title><source>Int J Environ Res Public Health</source>. <year>2021</year>;<volume>18</volume>:<fpage>9922</fpage>.<pub-id pub-id-type="pmid">34574843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph18189922</pub-id><pub-id pub-id-type="pmcid">PMC8471640</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajar</surname><given-names>R</given-names></name></person-group>. <article-title>PCSK 9 inhibitors: a short history and a new era of lipid-lowering therapy.</article-title><source>Heart Views</source>. <year>2019</year>;<volume>20</volume>:<fpage>74</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">31462965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/HEARTVIEWS.HEARTVIEWS_59_19</pub-id><pub-id pub-id-type="pmcid">PMC6686613</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rimbert</surname><given-names>A</given-names></name><name name-style="western"><surname>Smati</surname><given-names>S</given-names></name><name name-style="western"><surname>Dijk</surname><given-names>W</given-names></name><name name-style="western"><surname>Le May</surname><given-names>C</given-names></name><name name-style="western"><surname>Cariou</surname><given-names>B</given-names></name></person-group>. <article-title>Genetic inhibition of PCSK9 and liver function.</article-title><source>JAMA Cardiol</source>. <year>2021</year>;<volume>6</volume>:<fpage>353</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">33146683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamacardio.2020.5341</pub-id><pub-id pub-id-type="pmcid">PMC7643040</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagace</surname><given-names>TA</given-names></name></person-group>. <article-title>PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.</article-title><source>Curr Opin Lipidol</source>. <year>2014</year>;<volume>25</volume>:<fpage>387</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">25110901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MOL.0000000000000114</pub-id><pub-id pub-id-type="pmcid">PMC4166010</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Long</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Cholesterol in LDL receptor recycling and degradation.</article-title><source>Clin Chim Acta</source>. <year>2020</year>;<volume>500</volume>:<fpage>81</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">31770510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cca.2019.09.022</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shapiro</surname><given-names>MD</given-names></name><name name-style="western"><surname>Fazio</surname><given-names>S</given-names></name><name name-style="western"><surname>Tavori</surname><given-names>H</given-names></name></person-group>. <article-title>Targeting PCSK9 for therapeutic gains.</article-title><source>Curr Atheroscler Rep</source>. <year>2015</year>;<volume>17</volume>:<fpage>499</fpage>.<pub-id pub-id-type="pmid">25712137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11883-015-0499-4</pub-id><pub-id pub-id-type="pmcid">PMC5560054</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabatine</surname><given-names>MS</given-names></name><name name-style="western"><surname>Giugliano</surname><given-names>RP</given-names></name><name name-style="western"><surname>Keech</surname><given-names>AC</given-names></name><etal/></person-group>. <article-title>Evolocumab and clinical outcomes in patients with cardiovascular disease.</article-title><source>N Engl J Med</source>. <year>2017</year>;<volume>376</volume>:<fpage>1713</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">28304224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1615664</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robinson</surname><given-names>JG</given-names></name><name name-style="western"><surname>Farnier</surname><given-names>M</given-names></name><name name-style="western"><surname>Krempf</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.</article-title><source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>:<fpage>1489</fpage>&#8211;<lpage>99</lpage>.<pub-id pub-id-type="pmid">25773378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1501031</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDonagh</surname><given-names>M</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>K</given-names></name><name name-style="western"><surname>Holzhammer</surname><given-names>B</given-names></name><name name-style="western"><surname>Fazio</surname><given-names>S</given-names></name></person-group>. <article-title>A systematic review of PCSK9 inhibitors alirocumab and evolocumab.</article-title><source>J Manag Care Spec Pharm</source>. <year>2016</year>;<volume>22</volume>:<fpage>641</fpage>&#8211;<lpage>53q</lpage>.<pub-id pub-id-type="pmid">27231792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18553/jmcp.2016.22.6.641</pub-id><pub-id pub-id-type="pmcid">PMC10397903</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reyes-Soffer</surname><given-names>G</given-names></name><name name-style="western"><surname>Pavlyha</surname><given-names>M</given-names></name><name name-style="western"><surname>Ngai</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans.</article-title><source>Circulation</source>. <year>2017</year>;<volume>135</volume>:<fpage>352</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">27986651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.116.025253</pub-id><pub-id pub-id-type="pmcid">PMC5262523</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navarese</surname><given-names>EP</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>JG</given-names></name><name name-style="western"><surname>Kowalewski</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis.</article-title><source>JAMA</source>. <year>2018</year>;<volume>319</volume>:<fpage>1566</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">29677301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.2525</pub-id><pub-id pub-id-type="pmcid">PMC5933331</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasichayanula</surname><given-names>S</given-names></name><name name-style="western"><surname>Grover</surname><given-names>A</given-names></name><name name-style="western"><surname>Emery</surname><given-names>MG</given-names></name><etal/></person-group>. <article-title>Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor.</article-title><source>Clin Pharmacokinet</source>. <year>2018</year>;<volume>57</volume>:<fpage>769</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">29353350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-017-0620-7</pub-id><pub-id pub-id-type="pmcid">PMC5999140</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koskinas</surname><given-names>KC</given-names></name><name name-style="western"><surname>Windecker</surname><given-names>S</given-names></name><name name-style="western"><surname>Pedrazzini</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS).</article-title><source>J Am Coll Cardiol</source>. <year>2019</year>;<volume>74</volume>:<fpage>2452</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">31479722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2019.08.010</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ito</surname><given-names>MK</given-names></name><name name-style="western"><surname>Santos</surname><given-names>RD</given-names></name></person-group>. <article-title>PCSK9 inhibition with monoclonal antibodies: modern management of hypercholesterolemia.</article-title><source>J Clin Pharmacol</source>. <year>2017</year>;<volume>57</volume>:<fpage>7</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">27195910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.766</pub-id><pub-id pub-id-type="pmcid">PMC5215586</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stroes</surname><given-names>E</given-names></name><name name-style="western"><surname>Colquhoun</surname><given-names>D</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.</article-title><source>J Am Coll Cardiol</source>. <year>2014</year>;<volume>63</volume>:<fpage>2541</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">24694531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2014.03.019</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grze&#347;k</surname><given-names>G</given-names></name><name name-style="western"><surname>Dorota</surname><given-names>B</given-names></name><name name-style="western"><surname>Wo&#322;owiec</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Safety of PCSK9 inhibitors.</article-title><source>Biomed Pharmacother</source>. <year>2022</year>;<volume>156</volume>:<fpage>113957</fpage>.<pub-id pub-id-type="pmid">36411665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2022.113957</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabatine</surname><given-names>MS</given-names></name><name name-style="western"><surname>Giugliano</surname><given-names>RP</given-names></name><name name-style="western"><surname>Wiviott</surname><given-names>SD</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.</article-title><source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>:<fpage>1500</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">25773607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1500858</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>